Evidence map›Paper›PMID 41657786›Full record

ArticleAmerican journal of cancer research2026

Construction and validation of deep learning-based pathomics signature model for predicting postoperative recurrence of patients with clear cell renal cell carcinoma.

Yiren Yang, Jinxin Li, Yisha Gao, Wenqiang Liu, Baohua Zhu, Jie'an Ding, Linhui Wang, Xiaolei Shi, Wei Zhang

Abstract read
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiren YangDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Jinxin LiDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Yisha GaoDepartment of Pathology, Changhai Hospital, Naval Medical University Shanghai, China.
Wenqiang LiuDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Baohua ZhuDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Jie'an DingDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Linhui WangDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Xiaolei ShiDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.
Wei ZhangDepartment of Urology, Changhai Hospital, Naval Medical University Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study developed an attention-based multi-instance deep convolutional neural network (CRPNet) for the early prediction of postoperative recurrence in clear cell renal cell carcinoma (ccRCC). The model was trained on 183 whole slide images (WSIs) from ccRCC patients and validated on an internal cohort of 75 WSIs. Its prognostic performance was evaluated using Kaplan-Meier analysis, AUC, accuracy, precision, recall, false positive/negative rates (FPR/FNR), C-index, and hazard ratio (HR), and was compared against established tools including the UISS, SSIGN, and Karakiewicz nomograms. Results demonstrated that CRPNet-stratified high-risk groups had significantly poorer prognosis in both training and validation sets (P < 0.001), with consistency across subgroups based on T-stage, WHO/ISUP grade, and necrosis. In the training cohort, CRPNet achieved an AUC of 0.994 (95% CI: 0.974-1.000), accuracy of 97.70%, precision/recall of 95.56%, FPR of 1.55%, and FNR of 4.45%. In the validation cohort, it maintained an AUC of 0.879 (95% CI: 0.783-0.943), accuracy of 88.00%, precision of 85.71%, recall of 63.16%, FPR of 0%, and FNR of 36.84%, outperforming all comparator models. CRPNet also yielded a superior C-index compared to clinical parameters and traditional nomograms, and exhibited the highest HR (12.078, 95% CI: 1.611-90.539). In conclusion, CRPNet surpasses conventional prognostic models in recurrence prediction accuracy, AUC, precision, C-index, and risk stratification, while demonstrating lower FPR and FNR, thereby offering improved prognostication for metastatic ccRCC.

Indexed as

Clear cell renal cell carcinomaCRPNetdeep learningpathomicsrecurrence

Identifiers

PMID41657786
PMCPMC12877367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.